OKYO Pharma

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?

Sponsored

Phase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO Pharma

Sponsored

OKYO Pharma Reports First Patient Visit For Phase 2 Trial Of OK-101, To Fulfill One Of The Two Phase 3 Studies Required For FDA Approval If Successful

Sponsored

Phase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO Pharma

Sponsored

OKYO Pharma Reports First Patient Visit For Phase 2 Trial Of OK-101, To Fulfill One Of The Two Phase 3 Studies Required For FDA Approval If Successful

Sponsored

OKYO Pharma Activates First Clinical Trial Site For Phase 2 Study Of OK-101 To Treat Dry Eye Disease

Sponsored

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay

Sponsored

OKYO Pharma Activates First Clinical Trial Site For Phase 2 Study Of OK-101 To Treat Dry Eye Disease

Sponsored

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay

Sponsored

OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In Q2 2023, Anticipates Releasing Topline Results In Q4

Sponsored

OKYO Pharma's Trial Treating Subjects With DED Gets Listed On ClinicalTrials.gov

Sponsored

OKYO Pharma Recent News

OKYO Pharma CEO Gary Jacob Discusses The Company's Future Plans

Thank you for taking the time to answer my questions about OKYO Pharma. For our readers who may be unfamiliar with the company, can you just give us a brief introduction to the company?

Sponsored

OKYO Pharma's Drug OK-101 Clears Customs in the US; To Be Used In Phase 2, First-In-Human, Clinical Trial For Patients With Dry Eye Disease

OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) recently announced that its GMP packaged OK-101 drug to be used in the upcoming Phase 2, first-in-human, clinical trial in patients with DED, which was recently shipped from Europe, has cleared customs in the United States.

Sponsored

Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution

An eye condition that has been described as a common disease currently affects as many as 49 million Americans.

Sponsored